Shares of Sudarshan Pharma Industries fell by more than 3% on Monday following an inspection and search operation by the Goods and Services Tax (GST) department at the company’s registered office. The stock on the BSE hit an intra-day low of Rs 25.62 per share, marking a 3.06% decline. Despite the recent inspection, the company had reported improved financial performance for the December quarter.
Over the past year, Sudarshan Pharma’s stock has seen a decline of about 19%, as per official data. The company informed exchanges about the GST department’s inspection, search, and seizure operation at its registered office on February 21, 2026. Sudarshan Pharma stated that it is currently gathering information and cooperating with the authorities in response to the situation.
The company mentioned in its regulatory filing that the final report related to the search and seizure will follow the prescribed procedures. For the third quarter of FY26, Sudarshan Pharma recorded a net profit of Rs 4.15 crore, slightly up from Rs 3.9 crore in the same quarter the previous year. Revenue from operations also saw a significant increase to Rs 168 crore, compared to Rs 115.65 crore a year ago.
Earnings before interest, tax, depreciation, and amortization (EBITDA) for the company stood at Rs 23.4 crore, showing growth from Rs 16.6 crore in the corresponding period last year. However, the EBITDA margin decreased to 22.8% from 39.9% year-on-year. Sudarshan Pharma emphasized its focus on boosting exports and expanding manufacturing sales, along with efforts to enhance profit margins from the resale of active pharmaceutical ingredients (API) in domestic markets.
